www.nanomedinc.com carbon nanotube- based cancer therapeutics rob burgess, ph.d. founder and...
TRANSCRIPT
www.nanomedinc.com
Carbon Nanotube-Based Cancer Therapeutics
Rob Burgess, Ph.D.Founder and President
Medical Nanotechnologies Incorporated
MedNanoTech
2
Zyvex Corporation and Zyvex Performance Materials – Carbon Nanotube Functionalization
MedNanoTech
3
Zyvex Performance Materials’ Technical Approach
Two distinct functions: • Non-damaging binding to the CNT
• Customizable adhesion to host material (example: polymer such as epoxy)
Kentera™ Technology Enables CNTs in Composites
• Sizing agent or tailored coupling agent • Exfoliation of CNT • Uniform dispersion• Adhesion to polymer • Not a surfactant• Other advanced capabilities
— Process knowledge— Custom formulations
Zyvex NanoSolve® Enhanced Composites
MedNanoTech
4
Kentera-Conjugated Carbon Nanotubes are Soluble in Water
•Customizable side chains confer solubility
MedNanoTech
5
RF-mediated CNT Thermal Conductivity
RF
Transmitter
RF
Receiver
RF field
Source: Adapted from US Patent Application 2005/0251234 A1
Inventors: Kanzius et al.
Target
areaCNT-introduced
regions
Source: Gannon et al.
MedNanoTech
6
Source: Chakravarty et al.
Carbon nanotubes can be functionalized with antibodies and polar lipids.
Source: Marches et al.
AFM AFMTEM
CNT Functionalization
MedNanoTech
7
Intracellular Accumulation of PEDOT/PSS-Conjugated Carbon Nanotubes
72 hours post-treatmentSource: Draper et al.
HEK293 Cells
CNT Intracellular Delivery
MedNanoTech
8
Carbon nanotube properties make them a unique platform for therapeutic applications.
• Organized Structure• Mechanism of Action
Known• RF and Near IR
Sensitive• Electrically and
Thermally Conductive• Can be Functionalized
with a Variety of Molecules
• Can Penetrate Cells
MedNanoTech
9
Kentera and Kentera-conjugated carbon nanotubes are minimally cytotoxic.
Source: Draper et al.
CNT Cytotoxicity
MedNanoTech
10
Antibody/CNT Cell Surface Binding and Cytotoxicity
Source: Chakravarty et al.
Antibody/lipid-coated carbon nanotubes are noncytotoxic and bind specifically to cancer cells.
Source: Marches et al.
Daudi Cells
MedNanoTech
11
Cell Surface Binding
Source: Chakravarty et al.
Antibody-coated carbon nanotubes bind specifically to cancer cells.
MedNanoTech
12
CNT- Based Cancer Therapeutics
Source: Chakravarty et al.
Cancer cells are effectively ablated by carbon nanotubes in the presence of NIR light.
MedNanoTech
13
Panc-1 cells containing Kentera-conjugated carbon nanotubes are efficiently ablated upon RF exposure.
No SWNTs
11% PI Stained
SWNTs
99.7% PI Stained Source: Gannon et al.
CNT- Based Cancer Therapeutics
MedNanoTech
14
Kentera/SWNTs Kentera
H&E
TUNEL
Intratumoral CNT/Kentera injections demonstrate RF-mediated cellular ablation.
Source: Gannon et al.
MedNanoTech
15
Proposed Product Pipeline – Moving Towards Targeting CNTs
Monoclonal Antibody
Cell Surface Breast, Colorectal, Head and Neck
Her2, Erbitux
Small Molecule Cell Surface, Intracellular
Lung Tarceva, Iressa
Aptamer Cell Surface, Intracellular
Renal, Lung AS1411 (in dev.)
Peptide Cell Surface, Intracellular
Breast, Thyroid RGD (in dev.)
Targeting Agent
Mode of Action
Cancer Application
Known Example(s)
MedNanoTech
16
Criteria for Success: Targeted CNT Cancer Therapeutics
FunctionalityDispersion - Effective aqueous dispersion must be demonstrated. Efficacy – CNT’s must aggressively ablate targeted tissue.
• Toxicity – CNT’s and polymer functionalization must be demonstrated as nontoxic.
• Specificity – CNT’s must be successfully targeted to tumorigenic tissue and away from healthy tissue.
MedNanoTech
17
Acknowledgments
UT-DallasRocky Draper, Ph.D.Paul Pantano, Ph.D.Inga Musselman, Ph.D.
Zyvex CorporationJim Von EhrGareth Hughes, Ph.D.Tanja Kmecko
UT-MD Anderson Cancer Center
Steve Curley, M.D.
UT-SW Medical CenterEllen Vitetta, Ph.D.Radu Marches, Ph.D.Pavitra Chakravarty, Ph.D.
Nanoco, LLCPeter Wilk, M.D.
MedNanoTech
18
For Further Information
Rob Burgess, Ph.D.President
Medical Nanotechnologies, Inc.Email: [email protected]
Phone: 214-440-2311www.nanomedinc.com